Memo Therapeutics AG and Ono Pharmaceutical have entered into an antibody discovery partnership for immuno-oncology targets. The agreement validates Memo’s approach in immuno-oncology, a key strategy for its pipeline expansion beyond virus infections.
Memo Therapeutics AG (MTx) announced today the signing of a research and development collaboration agreement with Ono Pharmaceutical Co. Ltd. Under the terms of the agreement, MTx will leverage its best-in-class microfluidic single-cell molecular cloning and screening technologies to discover antibodies for immuno-oncology targets.
Ono will acquire intellectual property rights and worldwide exclusive rights to develop and commercialize therapeutic drug candidates with antibodies resulting from the collaboration. MTx will receive an upfront payment, research funding during the collaboration period, clinical development and sales milestones, as well as royalties on future sales.
“Ono with their proven track-record in the immune-oncology space is an ideal partner to advance this program. We are delighted to take this important step as the partnership recognizes our platform’s ability to identify high-value targets and create functionally superior antibodies in the immuno-oncology field,” said Dr. Christoph Esslinger, Chief Scientific Officer and founder of Memo Therapeutics AG.
“We look forward to collaborating with Memo Therapeutics AG’s team of antibody scientists through this collaboration and hope that the candidates generated through our collaboration will add to our current portfolio of medicines to help cancer patients in immuno-oncology,” said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono Pharmaceutical.
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. ONO focuses its research on the oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. In the fiscal year of 2021, the Japanese company Ono Pharmaceutical Co. Ltd. generated an annual revenue of approximately 361.4 billion Japanese yen (approx. $2.9 billion).
(Press release / SK)
Photo: Ono Pharmaceutical
Please login or sign up to comment.
Commenting guidelines